Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/Psilocybin/Eating Disorders

Psilocybin for Eating Disorders

12 papers and 12 clinical trials exploring psilocybin as a treatment for eating disorders.

CompoundClassic Psychedelic

Psilocybin

Psilocybin is a naturally occurring tryptamine psychedelic that acts as a prodrug to psilocin, a potent 5-HT2A receptor agonist. It is the furthest advanced psychedelic in clinical development, with two positive Phase III trials in treatment-resistant depression and expanding regulated access in Australia, Germany, and US states.

Full Psilocybin profile
Indication16 million people worldwide.

Eating Disorders

Eating disorders, including anorexia nervosa and bulimia nervosa, affect approximately 16 million individuals globally. The exploration of psychedelics, such as psilocybin and MDMA, as potential treatments for these conditions is a burgeoning field of research, showing promise in alleviating symptoms and improving quality of life.

Full Eating Disorders profile

Academic Research

12 papers
Open Accessmeta

Understanding experiences of psychedelic treatments for eating disorders: a meta-synthesis of qualitative studies

This meta-synthesis (s=8) of qualitative studies explored experiences of psychedelic treatment for eating disorders from the perspectives of people with eating disorders and providers. It found that perceived benefits centred on emotional processing and a stronger sense of connection with the body and self, while also highlighting the need for careful support because low weight and other physical vulnerabilities may increase risks.

Published
May 19, 2026
Journal
BMC Medicine
Authors
Morris, R., Gundogan, A., Lawrence, V., Himmerich, H., Treasure, J., Keeler, J. L.
Open Accessindividual

An open-label pilot study of psilocybin-assisted therapy for binge eating disorder

This open-label pilot study (n=5) tested a single 25 mg dose of psilocybin with Acceptance and Commitment Therapy-based psychotherapy in adults with binge eating disorder and found the treatment was feasible and well tolerated, with no serious adverse events. Participants reported fewer binge eating episodes, along with improvements in depression, anxiety and psychological flexibility over 14 weeks.

Published
January 3, 2026
Journal
Journal of Eating Disorders
Authors
Dallery, J., Miller, J. L., Boissoneault, J., Harvey, L., Ives, L., Knerr, A., Blaes, S., Ransom, M. N., Munson, M., Gilligan, J. P., Silverman, M. H., Guzzo, P. R., Loeser, B.
Open Accessindividual

Psilocybin’s acute and persistent brain effects: a precision imaging drug trial

This randomised, cross-over study (n=7) used precision functional mapping with high-resolution multi-echo fMRI to characterise psilocybin (25mg) versus methylphenidate effects on brain networks, revealing decreased network modularity during psilocybin exposure and reproducible network changes. Participants showed unique brain configurations and reported stronger mystical experiences with psilocybin compared to methylphenidate.

Published
June 5, 2025
Journal
Scientific Data
Authors
Subramanian, S., Renau, R., Perry, D., Chacko, R., Laumann, T. O., Flavin, K., Horan, C., Schweiger, J., Metcalf, N., Lenze, E. J., Snyder, A. Z., Dosenbach, N. U. F., Nicol, G., Siegel, J. S.
Open Accessindividual

Therapeutic emergence of dissociated traumatic memories during psilocybin treatment for anorexia nervosa

This case study (n=2) of an open-label pilot study (n=10) explores psilocybin-assisted psychotherapy for women with anorexia nervosa (AN or partial remission). Two participants experienced the therapeutic emergence of previously dissociated traumatic memories, leading to remission of AN symptoms and meaningful weight gain at 3-month follow-up.

Published
May 26, 2025
Journal
Journal of Eating Disorders
Authors
Peck, S. K., Knatz Peck, S., Brewerton, T. D., Fisher, H., Trim, J., Shao, S., Modlin, N. L., Kim, J., Finn, D. M., Kaye, W. H.
Paywallmeta

Beyond the 5-HT2A Receptor: Classic and Nonclassic Targets in Psychedelic Drug Action

This mini‑review argues that 5‑HT2A activation is only one facet of serotonergic psychedelic action, which also involves other serotonin receptors (5‑HT1A, 5‑HT2C), neurotrophin receptors (e.g. TrkB), promotion of neuroplasticity and possible protein post‑translational modifications. It highlights efforts to develop non‑hallucinogenic derivatives that retain therapeutic neuroplastic effects while minimising the intense psychedelic experience.

Published
November 8, 2023
Journal
Journal of Neuroscience
Authors
Cameron, L. P., Benetatos, J., Lewis, V., Bonniwell, E. M., Jaster, A. M., Moliner, R., Castrén, E., Mccorvy, J. D., Palner, M., Aguilar-Valles, A.
Open Accessmeta

Neuroimaging in psychedelic drug development: Past, present, and future

This review (2023) discusses the emerging field of psychedelic therapy for psychiatric disorders, emphasizing the potential of classic serotonergic psychedelics like psilocybin and LSD and substances like ketamine, MDMA, and ibogaine. It highlights the role of advanced neuroscientific research methods, particularly neuroimaging using Positron Emission Tomography (PET) and Magnetic Resonance Imaging (MRI), in advancing the understanding of drug and therapy effects on the brain. The article identifies key knowledge gaps, including the relationship between acute and longer-term effects, the precise characterization of effects at the 5-HT2A receptor, and the impact of these compounds on neuroplasticity, and proposes a roadmap for future research to address these questions through multimodal PET/MRI studies.

Published
September 27, 2023
Journal
Molecular Psychiatry
Authors
Wall, M. B., Harding, R., Zafar, R., Rabiner, E. A., Nutt, D. J., Erritzoe, D.

Clinical Trials

12 trials
Not yet recruitingPhase I

A Phase 1, Open-label, Single-arm Basket Trial of the Intravenously Administered Psilocin (TRP-8803): Safety, Anxiety, and Quality of Life Across Health Conditions Characterised by Cognitive Inflexibility, Emotional Distress, and Persistent Bodily Symptom Burden

This Phase 1, open‑label, single‑arm basket trial (N=66) tests the safety and early clinical effects of intravenous psilocin (TRP‑8803) administered in two dosing sessions alongside psychotherapy over a 6‑week treatment period, with a 12‑week follow‑up. Conducted in Australia and sponsored by Tryp Therapeutics, the study enrols participants across ten diagnostic cohorts — anorexia nervosa, body dysmorphic disorder, chronic fatigue, fibromyalgia, generalised anxiety disorder, irritable bowel syndrome, long COVID, major depressive disorder, obsessive–compulsive disorder and post‑traumatic stress disorder — to evaluate tolerability and signals of benefit in anxiety and quality of life. As a Phase 1 trial the primary outcomes focus on safety and tolerability (adverse events, vital signs and treatment‑emergent effects), with secondary or exploratory outcomes assessing changes in anxiety symptoms and health‑related quality of life using standardised, validated instruments. The single‑arm, open‑label design means there is no placebo or active comparator, and efficacy assessments are intended to generate preliminary, hypothesis‑generating data to inform the design of subsequent controlled studies. The study began recruitment in November 2025.

Started
November 3, 2025
Type
interventional
Blinding
none
Randomized
Yes
Registry ID
ACTRN12625000949482
Not yet recruitingPhase I

A Phase 1, Open-label, Pilot Study to Assess the Safety, Feasibility and Initial Efficacy of IV infused Psilocin (TRP-8803) Administration in Concert with Psychotherapy Among Adult Patients with Binge Eating Disorder (BED)

This Phase I open-label trial (n=12) will investigate the safety, feasibility, and initial efficacy of intravenous psilocin (TRP-8803), administered in two doses (ranging from 6.7 mg to 15 mg) two weeks apart, paired with psychedelic-assisted psychotherapy for adults with binge eating disorder (BED).

Started
June 1, 2025
Type
interventional
Blinding
none
Randomized
No
Registry ID
ACTRN12625000330448p
Not yet recruitingPhase I/II

The efficacy of psilocybin assisted psychotherapy (PAP) for treatment resistant obsessive-compulsive disorder (OCD), body dysmorphic disorder (BDD), and anorexia nervosa (AN); a pilot, single-arm basket trial

This single-arm, Phase I/II pilot trial (n=30) will test psilocybin-assisted psychotherapy (25mg x 2 doses, 4 weeks apart) for treatment-resistant obsessive-compulsive disorder (OCD), body dysmorphic disorder (BDD), and anorexia nervosa (AN).

Started
October 1, 2024
Type
interventional
Blinding
none
Randomized
No
Registry ID
ACTRN12624001160527
RecruitingPhase II

Study of Psilocybin for Anorexia in Young Adults (SPANYA)

Single-group interventional Phase II study (n=40) of psilocybin therapy for refractory Anorexia Nervosa in young adults with two dosing sessions (20 mg then up to 30 mg) plus preparatory and integration therapy.

Started
June 1, 2024
Type
interventional
Blinding
none
Randomized
No
Registry ID
NCT06399263
RecruitingPhase I

Toward Embodied Healing: Feasibility of a Psilocybin-Assisted Psychotherapy for Women with Partially Recovered Anorexia Nervosa and Persistent Body Image Disturbance. A Manualised, Three-Dose, Open-Label Case Study

This open-label Phase I trial (n=10) evaluated the safety and efficacy of psilocybin for anorexia nervosa body image disturbance.

Started
May 15, 2024
Type
interventional
Blinding
none
Randomized
Yes
Registry ID
ACTRN12624000343505
Not yet recruitingPhase I

Toward Embodied Healing: Feasibility of a Psilocybin-Assisted Psychotherapy for Partially Recovered Anorexia Nervosa and Persistent Body Image Disturbance. A Manualised, Three-Dose, Open-Label Case Study

Open-label, single-group Phase I feasibility study (n=10) of psilocybin-assisted psychotherapy (one 5 mg then two 25 mg oral doses) for body image disturbance in women with prior anorexia nervosa.

Started
April 1, 2024
Type
interventional
Blinding
none
Randomized
No
Registry ID
ACTRN12624000343505p

Explore further

Search all Psilocybin papers Search all Eating Disorders trials Full Psilocybin profile Full Eating Disorders profile